Skip to main content
Premium Trial:

Request an Annual Quote

Saga, Servier Sign Liquid Biopsy Services Deal

NEW YORK — Saga Diagnostics said on Tuesday that it has signed agreements to perform liquid biopsy testing on cancer patients enrolled in clinical studies for French pharmaceutical firm Servier.

Saga said that it will use its digital PCR-based Sagasafe platform to detect and quantify circulating tumor DNA (ctDNA) in patients from up to three Servier clinical trials. The deal, which also covers preclinical studies, runs for approximately two years.

Additional terms were not disclosed.

"These deals exemplify the increased demand we are experiencing for our offerings of ultrasensitive cancer analysis services and analysis kits," Saga CEO Lao Saal said in a statement. "We are excited to be working with Servier, who continues to choose us for important translational oncology projects."

Sagasafe — formerly known as IBSAFE — can detect ctDNA with a mutational allele frequency of 0.001 percent, according to Lund, Sweden-based Saga. The company has been using a recent $4.2 million fundraise for the ongoing commercialization of its kits and services, as well as to perform prospective clinical studies.